Influenza Vaccine Market - Forecasts from 2019 to 2024

January 2019 | 105 pages | ID: I2949EB8AFFEN
Knowledge Sourcing Intelligence LLP

Abstracts

The global influenza vaccine market is projected to grow at a CAGR of 6.37% to reach US$7.547 billion by 2024, from US$5.209 billion in 2018. Due to the constant changing of circulating influenza viruses, influenza vaccines strains are changed annually (for both the Northern Hemisphere and the Southern Hemisphere) to more closely match currently circulating virus strains (source: WHO). Hence the rising R&D expenditure and advancements in vaccine technology are driving the growth of the global influenza vaccine market in the forecast period. Furthermore, growing immunization for the prevention of influenza virus infection will emanate the market growth in the coming years and beyond.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global influenza vaccine value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global influenza vaccine market.

Major industry players profiled as part of the report are Seqirus, GlaxoSmithKline plc., Sanofi Pasteur SA., Novavax, Inc., Emergent BioSolutions Inc. among others.

Segmentation

The global influenza vaccine market has been analyzed through following segments:
By Vaccine Technology
Trivalent
Quadrivalent
By End-User
Children
Adolescents
Adults
Elderly
By Geography
North America
USA
Canada
Mexico
Others
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL INFLUENZA VACCINE MARKET BY VACCINE TECHNOLOGY

5.1. Trivalent
5.2. Quadrivalent

6. GLOBAL INFLUENZA VACCINE MARKET BY END-USER

6.1. Children
6.2. Adolescents
6.3. Adults
6.4. Elderly

7. GLOBAL INFLUENZA VACCINE MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. USA
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentia
  7.2.3. Others
7.3. Europe
  7.3.1. Germany
  7.3.2. France
  7.3.3. United Kingdom
  7.3.4. Spain
  7.3.5. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. Israel
  7.4.3. Others
7.5. Asia Pacific
  7.5.1. China
  7.5.2. Japan
  7.5.3. South Korea
  7.5.4. India
  7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Competition and Offerings Analysis of Key Vendors
8.2. Recent Investment and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Seqirus
9.2. GlaxoSmithKline plc.
9.3. Sanofi Pasteur SA.
9.4. Novavax, Inc.
9.5. Emergent BioSolutions Inc.
9.6. CSL Limited
9.7. Pfizer Limited
9.8. Gamma Vaccines Pty Ltd
9.9. BioDiem
9.10. F. Hoffmann-La Roche Ltd
LIST OF FIGURES
LIST OF TABLES
DISCLAIMER